Home > Insider Trading > Filing (0001415889-25-008711)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1623526	Stoke Therapeutics Inc.	STOK	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1522780	Md M. Edward Kaye	C/O Stoke Therapeutics, Inc. 45 Wiggins Avenue Bedford MA 01730		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-03-18	10,382	$8.67	148,253	No	4	S	Direct
Common Stock	Disposition	2025-03-19	8,907	$8.27	139,346	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Acquisiton	2025-03-20	216,000	$0.00	216,000	$8.33
Common Stock	Restricted Stock Units	Acquisiton	2025-03-20	144,000	$0.00	144,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
216,000		2035-03-19	No	4	A	Direct
144,000		2029-03-20	No	4	A	Direct

Footnotes

The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.11 to $8.925 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 3.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.06 to $8.95 per share, inclusive.
The option shall vest as to 1/48 of the total award on April 15, 2025, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
The award vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the issuer through each vesting date.